

United States Patent and Trademark Office

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/700,103	11/09/2000	Heinrich Gers-Barlag	BEIERSDORF 6	2589
. 7.	590 06/04/2003		-	
Norris McLaughlin & Marcus P A			EXAMINER	
220 East 42nd Street 30th Floor New York, NY 10017			LAMM, MARINA	
			ART UNIT	PAPER NUMBER
			1616	16
			DATE MAILED: 06/04/2003	1]

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)			
	09/700,103	GERS-BARLAG ET AL.			
Office Action Summary	Examiner	Art Unit			
	Marina Lamm	1616			
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply					
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filled after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). Status					
1)⊠ Responsive to communication(s) filed on <u>01 A</u>	Anril 2003				
	is action is non-final.				
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213. Disposition of Claims					
4)⊠ Claim(s) <u>7-12,14 and 15</u> is/are pending in the	application.				
4a) Of the above claim(s) is/are withdrawn from consideration.					
5) Claim(s) is/are allowed.					
6)⊠ Claim(s) <u>7-12,14 and 15</u> is/are rejected.					
7) Claim(s) is/are objected to.					
8) Claim(s) are subject to restriction and/or election requirement.					
Application Papers					
9)☐ The specification is objected to by the Examiner.					
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.					
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).					
11)☐ The proposed drawing correction filed on is: a)☐ approved b)☐ disapproved by the Examiner.					
If approved, corrected drawings are required in reply to this Office action.					
12) The oath or declaration is objected to by the Examiner.					
Priority under 35 U.S.C. §§ 119 and 120					
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).					
a) All b) Some * c) None of:					
1. Certified copies of the priority documents have been received.					
2. Certified copies of the priority documents have been received in Application No					
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 					
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).					
 a) ☐ The translation of the foreign language provisional application has been received. 15)☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121. 					
Attachment(s)					
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449) Paper No(s)	5) D Notice of Informal	y (PTO-413) Paper No(s) Patent Application (PTO-152)			
U.S. Patent and Trademark Office PTO-326 (Rev. 04-01) Office Ac	tion Summary	Part of Paper No. 19			

Application/Control Number: 09/700,103

Art Unit: 1616

DETAILED ACTION

Continued Examination Under 37 CFR 1.114

- 1. A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 2/3/03 has been entered.
- 2. Claims pending are 7-12, 14 and 15. Claim 7 has been amended to recite "non-crystallizing" composition.

Claim Rejections - 35 USC § 103

- 3. The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.
- 4. The rejection of Claims 7-12, 14 and 15 under 35 U.S.C. 103(a) as being unpatentable over Stäb et al. in view of Defossez et al. is maintained for the reasons of the record.

Response to Arguments

5. Applicant's arguments filed 2/3/03 have been fully considered but they are not persuasive.

The in response to the Applicant's argument that "there is no suggestion by either Stäb or Defossez that hexyldecyl laurate will have the surprising effect of avoiding crystallization when used in combination with the triazine compound," it is noted that Stäb et al. teach that their compositions "have a sufficiently high stability for use". See col. 3, line 21. Nowhere in the reference, Stäb et al. mentions that triazine compounds would crystallize in their formulations.

Application/Control Number: 09/700,103 Page 3

Art Unit: 1616

See Example 19. Therefore, absent showing to the contrary, it would have been obvious to one having ordinary skill in the art at the time the claimed invention was made to substitute isopropyl myristate of Stäb et al. for hexyldecyl laurate of Defossez et al. in the compositions of Stäb et al. with a reasonable expectation of deriving the same cosmetic effect as set forth in the Stäb reference because these two fatty acid esters are used interchangeably for the same

Conclusion

6. No claim is allowed at this time.

art-recognized purpose as suggested by Defossez et al.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Marina Lamm whose telephone number is (703) 306-4541. The examiner can normally be reached on Monday to Friday from 9 to 5.

The fax phone number for the organization where this application or proceeding is assigned is (703) 308-4556.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-1235.

Marina Laram

Patent Examiner AU 1616

6/3/03